IDRX, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2022-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.idrx.com
Clinical Trials
3
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
Phase 1
Recruiting
- Conditions
- Gastrointestinal NeoplasmsGastrointestinal Stromal Tumor (GIST)Digestive System DiseaseGastrointestinal DiseasesMetastatic Cancer
- Interventions
- First Posted Date
- 2022-08-05
- Last Posted Date
- 2025-09-17
- Lead Sponsor
- IDRx Inc. - A GSK Company
- Target Recruit Count
- 269
- Registration Number
- NCT05489237
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
News
No news found